Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Frye S, Crosby M, Edwards TP, Juliano R. US academic drug discovery. Nat Rev Drug Discov. 2011 Jun 1;10(6):409-10. doi: 10.1038/nrd3462
Phanikumar CV, Maitra B. Valuing urban bus attributes: an experience in Kolkata. J Public Transport. 2006;9(2):69-87. doi: 10.5038/2375-0901.9.2.4
Phani Kumar CV, Basu D, Maitra B. Modeling generalized cost of travel for rural bus users: a case study. J Public Transport. 2004;7(2):59-72. doi: 10.5038/2375-0901.7.2.4